Kalaris Therapeutics
KLRS
52 hedge funds and large institutions have $24.6M invested in Kalaris Therapeutics in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 17 closing their positions.
0.17% more ownership
Funds ownership: 1.69% → 1.87% (+0.17%)
12% less funds holding
Funds holding: 59 → 52 (-7)
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
32% less capital invested
Capital invested by funds: $36.3M → $24.6M (-$11.7M)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$437K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$363K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$297K |
| 4 |
Squarepoint
New York
|
+$222K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$81.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.16M |
| 2 |
AI
Acuitas Investments
Seattle,
Washington
|
-$865K |
| 3 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$275K |
| 4 |
Renaissance Technologies
New York
|
-$261K |
| 5 |
D.E. Shaw & Co
New York
|
-$240K |
KLRS Hedge Fund Activity: Q4 2024 in Review
52 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q4 2024, worth a combined $24.6M — down 32% from $36.3M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of KLRS and 11 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 11 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $437K. The largest seller was EcoR1 Capital, cutting an estimated $7.16M.
- 52 institutional investors held Kalaris Therapeutics (KLRS) as of Q4 2024, down from 59 in Q3 2024.
- Funds reported $24.6M of Kalaris Therapeutics stock for Q4 2024, down 32% quarter-over-quarter.
- 11 funds opened new Kalaris Therapeutics positions in Q4 2024 and 17 closed out, a net change of -6 holders.
- The largest Kalaris Therapeutics buyer in Q4 2024 was Jacobs Levy Equity Management, an estimated $437K added.
- The largest Kalaris Therapeutics seller in Q4 2024 was EcoR1 Capital, an estimated $7.16M sold.
Based on aggregated 13F filings for Q4 2024.